Status:
RECRUITING
Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer
Lead Sponsor:
University Health Network, Toronto
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate ca...
Eligibility Criteria
Inclusion
- Age \> 18 years.
- Able to provide informed consent.
- Histologic diagnosis of prostate adenocarcinoma.
- ECOG performance status 0-1.
- High-risk localized disease by NCCN criteria (\>cT3, Grade group \>4, or PSA \>20 ng/mL) or clinical N1 disease.
- Clinical M0 by conventional imaging (computed tomography (CT) and bone scan (BS)) and/or molecular imaging (prostate specific membrane antigen (PSMA)- positron emission tomography (PET))
Exclusion
- Prior pelvic radiotherapy.
- Contraindications to radiotherapy
Key Trial Info
Start Date :
July 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2030
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05313815
Start Date
July 18 2022
End Date
July 1 2030
Last Update
June 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Center
Toronto, Ontario, Canada, M5G 2M9